Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.
Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.
Get the full story at our sister site, Drug Delivery Business News.
[Photo by Fusion Medical Animation on Unsplash]
Two U.S. government agencies today announced an agreement with Pfizer (NYSE:PFE) for production and delivery of 100 million doses of a COVID-19 vaccine.The U.S. Dept. of Health and Human Services, along with the U.S. Defense Dept., agreed to the large-scale production and U.S. delivery deal once Pfizer’s vaccine is successfully manufactured and approved. In addition to the 100 million doses initially agreed upon. the U.S. government will be able to acquire an additional 500 million doses.
Get the full story at our sister site, Drug Discovery & Development.
[Image from Unsplash]
Two U.S. government agencies today announced an agreement with Pfizer (NYSE:PFE) for production and delivery of 100 million doses of a COVID-19 vaccine.The U.S. Dept. of Health and Human Services, along with the U.S. Defense Dept., agreed to the large-scale production and U.S. delivery deal once Pfizer’s vaccine is successfully manufactured and approved. In addition to the 100 million doses initially agreed upon. the U.S. government will be able to acquire an additional 500 million doses.
Get the full story at our sister site, Drug Discovery & Development.
[Image from Unsplash]
The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate.Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or, should the FDA grant emergency use authorization (EUA) or approval, the government would be able to distribute the doses as part of a COVID-19 vaccine campaign, according to a news release.
Get the full story at our sister site, Pharmaceutical Processing World.
Medtech stocks continue to fluctuate amid the COVID-19 pandemic, with a significant dip in the shares belonging to the industry’s biggest names.
MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 81.88 points at the end of last week (June 26). That total represents a -3.7% decrease from the 85.00-point total at the same time a week prior (June 19), demonstrating another downturn after a 3.5% bump just one week before.
Meanwhile, the S&P 500 Index experienced a -2.9% drop from June 19 to June 26, and the Dow Jones Index fared slightly worse with a -3.3% decrease over the same period of time. Both indexes mirrored the medtech industry’s changes, having each posted marginal increases the week before.
Medtech’s lowest point during the COVID-19 pandemic remains at 62.13 on March 23. Since then, the industry’s stocks have experienced 31.8% growth in total. Stocks in the industry remai…
The head of the newly formed U.S. International Development Finance Corp. (DFC) said this week that the agency could provide tens of billions of dollars in financing to return manufacturing to the United States, according to a report by Reuters.
One of the projects it may finance is a $12 billion semiconductor plant from Taiwan, DFC CEO Adam Boehler told the news agency.
Working with the Department of Defense, the DFC recently launched a request for proposals from companies seeking financing under the Defense Production Act, which prioritizes government orders amid a war or national crisis. The defense department announced on June 22 that it will dedicate $100 million authorized by the CARES Act to boost medtech and pharmaceutical manufacturing in the U.S. The Trump administration has been pushing to return U.S. manufacturing to this country from China.
Boehler told Reuters that the new finance agency has received a lot of attention from companies, and t…
The U.S. Department of Defense announced today that it will dedicate $100 million authorized by the CARES Act to boost medtech and pharmaceutical manufacturing in the U.S.
Working with DOD, the U.S. International Development Finance Corporation (DFC) launched a request for proposals from companies seeking financing under the Defense Production Act, which prioritizes government orders amid a war or national crisis.
Get the full story on our sister site MassDevice.
The U.S. Department of Defense announced today that it will dedicate $100 million authorized by the CARES Act to boost medtech and pharmaceutical manufacturing in the U.S.
Working with DOD, the newly formed U.S. International Development Finance Corporation (DFC) launched a request for proposals from companies seeking financing under the Defense Production Act, which prioritizes government orders amid a war or national crisis.
The Trump administration has invoked the Korean-War-era law to require certain manufacturers to produce critically needed ventilators and personal protective equipment during the COVID-19 pandemic. For example, the president ordered General Motors in March to start producing ventilators for COVID-19 patients. In April, the defense department awarded $133 million in N95 respirator contracts to 3M (NYSE:MMM), Owens & Minor (NYSE:OMI) and Honeywell (NYSE:HON) under the act.
In the latest initiative, eligible projects should help …
The U.S. Dept. of Health & Human Services (HHS) and Dept. of Defense (DoD) announced a joint effort to increase manufacturing for vials earmarked for COVID-19-related drugs and vaccines.
The Biomedical Advanced Research and Development Authority (BARDA), as part of HHS, collaborated with DoD to provide funding for U.S.-based companies Corning Inc. and SiO2 Materials Science.
Get the full story at our sister site, Pharmaceutical Processing World.
The U.S. Dept. of Health & Human Services (HHS) and Dept. of Defense (DoD) announced a joint effort to increase manufacturing for vials earmarked for COVID-19-related drugs and vaccines.
The Biomedical Advanced Research and Development Authority (BARDA), as part of HHS, collaborated with DoD to provide funding for U.S.-based companies Corning Inc. and SiO2 Materials Science.
Under the Trump Administration’s “Operation Warp Speed,” HHS and DoD plan to scale up domestic manufacturing capacity for the vials that could be needed for vaccines and drugs in response to the ongoing COVID-19 pandemic, as well as future public health emergencies, according to a news release.
BARDA is partnering with and offering $204 million to Corning in return for manufacturing capacity expansion to produce an additional 164 million Valor glass vials each year if needed. Corning will accelerate manufacturing at its facilities in Durham, N.C., Big Flats, N.Y…
ExThera Medical announced today that the U.S. Defense Dept. selected its Seraph 100 Microbind affinity blood filter for a U.S.-based clinical trial.
The randomized, controlled, multi-center trial will be funded by the DoD and run by investigators at the Uniformed Services University in Bethesda, Md. It comes on the back of encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the U.S., as well as 14 other hospitals in Europe, according to a news release.
Initial reports show that Seraph 100 stabilizes blood pressure and inflammatory biomarkers that correlate with poor patient outcomes, as IL-6, Ferritin, D-dimers, LDH and Nt-proBNP all decreased during Seraph 100 treatments of COVID-19 patients.
The blood filter, which won CE Mark approval in August 2019, could improve patient outcomes by providing additional time for care while reducing sources of inflammation and possibly preventing further damag…